Program:
As the first antisense therapeutics make their way to the market in 1997, dramatic advances in
understanding the technology¹s mechanism of action, toxicology, and pharmacokinetics are
establishing it as a broadly based tool for drug development. Accompanying this validation of
antisense as a clinical tool, advances in the Human Genome Projectand other areas of basic
researchhave produced an explosion in the use of antisense as a functional assay for drug
discovery. The combination of these eventsas well as the technical improvements in manufacturing
of commercial-scale antisense oligossuggests that antisense will emerge during 1997 as a core
technology for drug discovery and development that will be applicable literally from benchtop to
bedside. Antisense ¹97: Targeting the Molecular Basis of Disease presents the state of the art
in these developments.
Registration :
Cambridge Healthtech Institute
1037 Chestnut Street
Newton Upper Falls, MA 02164
USA
Phone: 617-630-1300
Fax: 617-630-1325
Deadline for Abstracts: 03/7/97
Email for Requests and Registration: chi@healthtech.com